Active versus passive immunization against hepatitis A in the Israel defence forces: a cost–benefit analysis
| Autor: | Ofer Shpilberg, Nir Yetiv, David Gillis, Isaac Ashkenazi, Joshua Shemer, Arieh Eldad, Michael Gdalevich, Daniel Mimouni |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
Viral Hepatitis Vaccines Cost-Benefit Analysis Immune serum globulin Hepatitis A vaccine Hepatitis A Antibodies Active immunization medicine Humans Hepatitis Antibodies Hepatitis A Vaccines General Veterinary General Immunology and Microbiology Cost–benefit analysis business.industry Vaccination Immunization Passive Public Health Environmental and Occupational Health virus diseases Hepatitis A medicine.disease Military personnel Military Personnel Infectious Diseases Vaccines Inactivated Immunization Immunology Molecular Medicine business Demography |
| Zdroj: | Vaccine. 18:3005-3010 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/s0264-410x(00)00091-8 |
| Popis: | We compared cost-benefit and cost-effectiveness analyses of hepatitis A prevention with immune serum globulin (ISG) vs inactivated hepatitis A vaccine (iHAV) in the Israel Defence Forces. Personnel were grouped according to conditions and duration of service and analyses were performed based on maximum and minimum hepatitis A projected incidences for each group. For standing army soldiers in field units, iHAV is economically superior compared with ISG. For the five other groups studied, the reverse is true. Expected increases in production costs of ISG and expected decreases in costs of iHAV are likely to make iHAV more economical in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect